Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology.

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Sara H M Bengtsson, Lerna M Gulluyan, Gregory J Dusting, Grant R Drummond
{"title":"Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology.","authors":"Sara H M Bengtsson,&nbsp;Lerna M Gulluyan,&nbsp;Gregory J Dusting,&nbsp;Grant R Drummond","doi":"10.1046/j.1440-1681.2003.03929.x","DOIUrl":null,"url":null,"abstract":"<p><p>1. Vascular cells have evolved to use reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, as signalling molecules. Under physiological conditions, ROS are important regulators of cell cycle, protein kinase activity and gene expression. However, in vascular disease states, such as hypertension and hypercholesterolaemia, excessive production of ROS may overwhelm the anti-oxidant defence mechanisms of cells, resulting in 'oxidative stress', damage to the artery wall and, ultimately, development of atherosclerotic plaques. 2. The primary source of ROS in the vasculature is NADPH oxidase. There appear to be at least three isoforms of NADPH oxidase expressed in the vascular wall, each differing with respect to the flavin-containing catalytic subunit it uses to transfer electrons from NADPH to molecular oxygen. Thus, although endothelial cells and adventitial fibroblasts express a gp91phox-containing NADPH oxidase similar to that originally identified in phagocytes, vascular smooth muscle cells may rely on novel homologues of gp91phox, namely Nox1 and Nox4, to produce superoxide. 3. Controversy remains over which isoform(s) of NADPH oxidase is responsible for the oxidative stress associated with vascular diseases. We and others have shown that although gp91phox mRNA expression is upregulated during atherogenesis in human and animal models, expression of the Nox4 subunit remains unchanged. Nox1 expression is also likely to be increased in diseased arteries; however, its relative level of expression, at least at the mRNA level, appears to be markedly lower than that of the other gp91phox homologues, even after upregulation. 4. Whether these findings suggest that a gp91phox-containing NADPH oxidase is more important than either Nox4 or Nox1 in vascular disease awaits studies examining relative protein expression and enzyme kinetics of each subunit, as well as the effects of targeted gene deletion of each of these gp91phox homologues on atherogenesis.</p>","PeriodicalId":10259,"journal":{"name":"Clinical and Experimental Pharmacology and Physiology","volume":"30 11","pages":"849-54"},"PeriodicalIF":2.4000,"publicationDate":"2003-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1440-1681.2003.03929.x","citationCount":"133","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Pharmacology and Physiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/j.1440-1681.2003.03929.x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 133

Abstract

1. Vascular cells have evolved to use reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, as signalling molecules. Under physiological conditions, ROS are important regulators of cell cycle, protein kinase activity and gene expression. However, in vascular disease states, such as hypertension and hypercholesterolaemia, excessive production of ROS may overwhelm the anti-oxidant defence mechanisms of cells, resulting in 'oxidative stress', damage to the artery wall and, ultimately, development of atherosclerotic plaques. 2. The primary source of ROS in the vasculature is NADPH oxidase. There appear to be at least three isoforms of NADPH oxidase expressed in the vascular wall, each differing with respect to the flavin-containing catalytic subunit it uses to transfer electrons from NADPH to molecular oxygen. Thus, although endothelial cells and adventitial fibroblasts express a gp91phox-containing NADPH oxidase similar to that originally identified in phagocytes, vascular smooth muscle cells may rely on novel homologues of gp91phox, namely Nox1 and Nox4, to produce superoxide. 3. Controversy remains over which isoform(s) of NADPH oxidase is responsible for the oxidative stress associated with vascular diseases. We and others have shown that although gp91phox mRNA expression is upregulated during atherogenesis in human and animal models, expression of the Nox4 subunit remains unchanged. Nox1 expression is also likely to be increased in diseased arteries; however, its relative level of expression, at least at the mRNA level, appears to be markedly lower than that of the other gp91phox homologues, even after upregulation. 4. Whether these findings suggest that a gp91phox-containing NADPH oxidase is more important than either Nox4 or Nox1 in vascular disease awaits studies examining relative protein expression and enzyme kinetics of each subunit, as well as the effects of targeted gene deletion of each of these gp91phox homologues on atherogenesis.

NADPH氧化酶在血管生理和病理生理中的新亚型。
1. 血管细胞已经进化到使用活性氧(ROS),如超氧化物和过氧化氢,作为信号分子。生理条件下,ROS是细胞周期、蛋白激酶活性和基因表达的重要调节因子。然而,在血管疾病状态下,如高血压和高胆固醇血症,ROS的过量产生可能会压倒细胞的抗氧化防御机制,导致“氧化应激”,损害动脉壁,最终形成动脉粥样硬化斑块。2. 血管中ROS的主要来源是NADPH氧化酶。在血管壁上至少有三种NADPH氧化酶的同工异构体表达,每一种都不同于它用来将电子从NADPH转移到分子氧的含有黄素的催化亚基。因此,尽管内皮细胞和外层成纤维细胞表达一种与最初在吞噬细胞中发现的gp91phox类似的含有gp91phox的NADPH氧化酶,血管平滑肌细胞可能依赖gp91phox的新同源物,即Nox1和Nox4来产生超氧化物。3.关于NADPH氧化酶的哪个异构体负责与血管疾病相关的氧化应激,仍然存在争议。我们和其他人已经证明,尽管在人类和动物模型中,gp91phox mRNA的表达在动脉粥样硬化过程中上调,但Nox4亚基的表达保持不变。病变动脉中Nox1表达也可能升高;然而,即使上调后,其相对表达水平,至少在mRNA水平上,似乎明显低于其他gp91phox同源物。4. 这些发现是否表明含有gp91phox的NADPH氧化酶在血管疾病中比Nox4或Nox1更重要,有待研究检测每个亚基的相对蛋白表达和酶动力学,以及这些gp91phox同源物的靶向基因缺失对动脉粥样硬化的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Experimental Pharmacology and Physiology
Clinical and Experimental Pharmacology and Physiology PHARMACOLOGY & PHARMACY-PHYSIOLOGY
自引率
0.00%
发文量
128
期刊介绍: Clinical and Experimental Pharmacology and Physiology is an international journal founded in 1974 by Mike Rand, Austin Doyle, John Coghlan and Paul Korner. Our focus is new frontiers in physiology and pharmacology, emphasizing the translation of basic research to clinical practice. We publish original articles, invited reviews and our exciting, cutting-edge Frontiers-in-Research series’.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信